secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001193125-23-172528
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharmaceuticals files lawsuit challenging FDA approval of Lumryz
---------------------------------------------------------------------

- Filed complaint in U.S. District Court for DC seeking to vacate FDA's May 1, 2023 approval of Lumryz NDA.
- Alleges FDA acted outside Orphan Drug Act by granting Lumryz ODE despite Xywav's unexpired exclusivity.
- Claims FDA's finding of clinical superiority (once-nightly dosing) lacks substantial evidence and is inconsistent with prior determinations.
- Seeks declaration that approval was arbitrary, capricious, and in excess of statutory authority.
- Jazz cannot predict outcome or impact on oxybate business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312523172528/0001193125-23-172528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312523172528/d491392d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-172528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer